AI assistant
USCOM LIMITED — Capital/Financing Update 2012
Oct 16, 2012
65979_rns_2012-10-16_6007bb38-61ee-430d-9f71-c8d47db14d62.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au
M A R K E T A N N O U N C E M E N T
Successful quarter for USCOM operations
Wednesday 17th of October 2012: Uscom (ASX code: UCM).
Uscom Ltd today released commentary to accompany the September quarter Appendix 4C. The 4C confirmed that USCOM met budget and decreased costs for the quarter and its cash position was complimented by the recent successful capital raising.
The Appendix 4C reported a quarterly loss of $344k against a budgeted loss of $341k with a net operating cash outflow of $307k. This result was achieved by steady sales and decreased costs. The cash on hand at the end of the quarter was $1,166,114 compared to $544,463 at the end of the previous quarter.
Executive Chairman of Uscom, Rob Phillips said, “These results reflect steady sales and sound cash control and comes on the heels of our recent successful capital raising. During this period we have been focused on stabilizing the business, capital raising and developing a strategic path forward. While not stellar, these results confirm that we can achieve our plans for the Company even in the current global environment. We have had a number of significant academic developments in this quarter which should support our global marketing activities and feed into sales in the coming quarters. We are looking forward to the remainder of this financial year as we execute our broader commercial strategy.”
About Uscom
Uscom Limited is an Australian medical device company which listed on the Australian Stock Exchange in December 2003. Uscom has developed a Non Invasive Cardiac Output Monitor. The USCOM is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency and Intensive Care Medicine and Anesthesia, and is a tool of choice for management of adult and paediatric sepsis, and for the guidance of fluid therapy.
USCOM has global regulatory approval and the device is currently marketed in North America, South America, Europe, the Middle East, Australia & New Zealand, China and SE Asia.
Uscom Contacts Rob Phillips Executive Chairman [email protected]
Tom Rowe Company Secretary [email protected]